AHA 2012 in Los Angeles - Cardiology Conference Coverage

LBCT.01. Late-Breaking Clinical Trials: Practice Implications for CAD and VTE
Sun, Nov 4, 3:30–5:20 PM
Moderators:
Elliott Antman, Boston, MA
Frans Van de Werf, Leuven, Belgium
Gary H Gibbons, Bethesda, MD

		Aspirin for the Prevention of Recurrent Venous Thromboembolism After a First Unprovoked Event: Results of the ASPIRE Randomized Controlled Trial Timothy Brighton, South Eastern Area Lab Services (SEALS), Prince of Wales Hospital, Sydney, Australia Discussant: Mary Cushman, Colchester, VT
		A Randomized Trial of Bedside Platelet-Function Monitoring to Adjust Antiplatelet Therapy vs Standard of Care in Patients Undergoing Drug-Eluting Stent Implantation: The ARCTIC Study Gilles Montalescot, Pitié-Salpêtrière University Hospital, Paris, France Discussant: Eric R Bates, Ann Arbor, MI
		First Large-Scale Platelet-Function Evaluation in an Acute Coronary Syndromes Trial: The TRILOGY ACS Platelet-Function Substudy Paul A Gurbel, Sinai Hospital Center for Thrombosis Research, Baltimore, MD Discussant: Lars Wallentin, Uppsala, Sweden
		Results of the Trial to Assess Chelation Therapy Gervasio A Lamas, Mount Sinai Medical Center, Miami, FL Discussant: Paul W Armstrong, Edmonton, AB
		Main Results of the Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM) Trial Valentin Fuster, Mount Sinai School of Medicine, New York, NY Discussant: Alice K Jacobs, Boston, MA

LBCT.02. Late-Breaking Clinical Trials: Health Economics and Quality of Life in Contemporary Trials
Sun, Nov 4, 5:30–6:45 PM
Moderators:
Mikhail Kosiborod, Kansas City, MO
Fausto Pinto, Lisbon, Portugal

		Prospective Evaluation of Outcomes With Stress Perfusion Imaging vs Stress Wall Motion Imaging During Dobutamine or Exercise Echocardiography Thomas R Porter, University of Nebraska Medical Center, Omaha Discussant: Gerald M Pohost, Los Angeles
		Economic Outcomes of Percutaneous Coronary Intervention Performed at Sites With and Without On-Site Cardiac Surgery Eric L Eisenstein, Duke Clinical Research Institute, Durham, NC
		Quality-of-Life Outcomes in the Trial to Assess Chelation Therapy (TACT) Daniel B Mark, Duke University Medical Center, Durham, NC
		Cost-Effectiveness of PCI with Drug-Eluting Stents vs Bypass Surgery for Patients with Diabetes and Multivessel Coronary Artery Disease: Results from the FREEDOM Trial Elizabeth A Magnuson, Saint Luke's Mid America Heart Institute, Kansas City, MO
		Discussants: (Clinical Implications of CPORT-E, TACT, and FREEDOM trials) David O Williams, Boston, MA Mark Hlatky, Stanford, CA

LBCT.03. Late-Breaking Clinical Trials: Treatments for Prevention of Cardiovascular Events: A Population Perspective
Mon, Nov 5, 9:00–10:16 AM
Moderators:
Donna K Arnett, Birmingham, AL
William Zoghbi, Houston, TX

		Omega-3 Fatty Acids for the Prevention of Recurrent Symptomatic Atrial Fibrillation: Results of a double-blind randomized clinical trial (FORWARD) Alejandro Macchia, Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy Discussant: Christine Albert, Boston, MA
		Fish Oil for the Prevention of Post-Operative Atrial Fibrillation: The Omega-3 Fatty Acids for Prevention of Post-Operative Atrial Fibrillation (OPERA) Trial Roberto Marchioli, Consorzio Mario Negri Sud, Santa Maria Imbaro, Italy Discussant: Ali Oto, Ankara, Turkey
		A Randomized Trial of a Multivitamin in the Prevention of Cardiovascular Disease in Men: The Physicians' Health Study II Howard D Sesso, Brigham and Women's Hospital, Boston, MA Discussant: Sidney C Smith, Chapel Hill, NC
		Use of a Multidrug Pill in Reducing Cardiovascular Events (UMPIRE) Simon A Thom, Imperial College London, UK Discussant: Andrew M Tonkin, Melbourne, Australia

LBCT.04. Late-Breaking Clinical Trials: Novel Treatments for Managing Lipid Disorders
Mon, Nov 5, 10:45–11:55 PM
Moderators:
Robert H Eckel, Aurora, CO
Frank Sacks, Boston, MA

		Overview of PCSK9 Inhibition in the Treatment of Hyperlipidemia Jay Horton, University of Texas Southwestern, Dallas
		Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD): Interim Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Frederick Raal, University of Witwatersrand, Johannesburg, South Africa
		Goal Achievement after Utilizing an Anti-PCSK9 Antibody in Statin-Intolerant Subjects (GAUSS): Interim Results from a Randomized, Double-Blind, Placebo-Controlled Study Evan Stein, Metabolic and Atherosclerosis Research Center, Cincinnati, OH
		Effects of 12 Weeks of Treatment with RN316 (PF-04950615), a Humanized IgG2Δa Monoclonal Antibody Binding Proprotein Convertase Subtilisin Kexin Type 9, in Hypercholesterolemic Subjects on High- and Maximal-Dose Statins Barry Gumbiner, Pfizer, San Diego, CA
		Discussant: (RUTHERFORD, GAUSS, and RN316) Peter Wilson, Atlanta, GA
		CaPre, A Novel Class of Omega-3 Phospholipids, Therapy in Patients With Mild-to-High Hypertriglyceridemia (from the Multicenter Placebo-Controlled, Randomized, Double-Blind 12-week Trial for Efficacy of CaPre on Hypertriglyceridemia [TRIFECTA]) Jacques Genest, McGill University Health Center, Montreal, QC Discussant: Robert H Eckel, Aurora, CO
		Effects of the Cholesteryl Ester Transfer Protein Inhibitor Dalcetrapib in Patients with Recent Acute Coronary Syndrome Gregory G Schwartz, University of Colorado, Denver Discussant: Alan Tall, New York, NY

LBCT.05. Late-Breaking Clinical Trials: Cell-Based Therapies for Myocardial Regeneration
Tue, Nov 6, 10:45 AM–12:00 PM
Moderators:
Stefanie Dimmeler, Frankfurt, Germany
Charles E Murry, Seattle, WA

		Overview of the Field of Cell-Based Therapies for Myocardial Regeneration Stefanie Dimmeler, Frankfurt, Germany
		Results of the Swiss Multicenter Intracoronary Stem Cells Study in Acute Myocardial Infarction (Swiss AMI) Trial Daniel Sürder, Fondazione Cardiocentro Ticino, Lugano, Switzerland
		The ALCADIA (Autologous Human Cardiac-Derived Stem Cell to Treat Ischemic Cardiomyopathy) Trial Naofumi Takehara, Kyoto Prefectural University of Medicine, Kyoto, Japan
		The Effect of Timing of Stem-Cell Delivery Following Acute Myocardial Infarction: The NHLBI and CCTRN TIME Trial Jay H Traverse, Minneapolis Heart Institute, MN
		Comparison of Allogeneic vs Autologous Mesenchymal Stem Cells in Patients with Ischemic Cardiomyopathy Joshua M Hare, University of Miami Miller School of Medicine, FL
		Effect of Cardiac Stem Cells in Patients with Ischemic Cardiomyopathy: Interim Results of the SCIPIO Trial Up to 2 Years After Therapy Roberto Bolli, University of Louisville, KY
		Panel discussion (includes moderators): Marc S Penn, Akron, OH Joseph C Wu, Stanford, CA Philippe Menasche, Paris, France

LBCT.06. Late-Breaking Clinical Trials: Management of LV Dysfunction: Devices and Drugs
Tue, Nov 6, 3:45–5:35 PM
Moderators:
Mariell Jessup, Philadelphia, PA
Wilson Tang, Cleveland, OH

		MADIT Randomized Trial to Reduce Inappropriate Therapy (MADIT-RIT) Arthur J Moss, University of Rochester Medical Center, NY Discussant: Douglas P Zipes, Indianapolis, IN
		Biventricular vs Right Ventricular Pacing in Patients with Left Ventricular Dysfunction and Atrioventricular Block (BLOCK HF Study) Anne B Curtis, University at Buffalo, NY Discussant: Gerasimos S Filippatos, Athens, Greece
		Pilot Trial of Two Levels of Hypothermia in Comatose Survivors from Out-of-Hospital Cardiac Arrest Esteban Lopez-de-Sa, Hospital Universitario La Paz, Madrid, Spain Discussant: Graham Nichol, Seattle, WA
		The Relaxin in Acute Heart Failure (RELAX-AHF) Trial John R Teerlink, San Francisco Veterans Affairs Medical Center, University of California, San Francisco Discussant: John McMurray, Glasgow, Scotland
		Cardiorenal Rescue Study in Acute Decompensated Heart Failure: Results of CARRESS-HF, for the Heart Failure Clinical Research Network Bradley A Bart, Hennepin County Medical Center, Minneapolis, MN Discussant: Milton Packer, Dallas, TX